Prostamax Research Overview (also known as Prostamax prostate bioregulator, Khavinson prostate peptide, Tryptamine prostate peptide)
A peptide studied for prostate-cell structural support, prostate inflammatory signaling regulation, and epigenetic stabilization. Research interest includes male longevity and prostate health applications. Often combined with Testagen and Libidon in male optimization research.
What Is Prostamax?
Prostamax is a peptide bioregulator developed by Professor Vladimir Khavinson specifically targeting prostate tissue. Like Libidon, it is designed to restore normal gene expression in aging prostate cells, but with a different peptide sequence providing complementary coverage of prostate cell biology.
Prostate Aging and BPH
Benign prostatic hyperplasia (BPH) affects over 50% of men by age 60 and over 80% by age 80. Its development reflects altered hormonal signaling, increased stromal growth factor signaling, and reduced apoptotic pruning of proliferating prostate cells. Prostamax is designed to normalize prostate cell gene expression, potentially reducing the proliferative imbalance underlying BPH.
Research Applications
Animal studies with Prostamax have shown reduction in prostate gland volume parameters in aged animals, improved histological scores of glandular architecture, and normalization of secretory cell function. Russian clinical research has documented improvements in IPSS (International Prostate Symptom Score) and urinary flow parameters in elderly men receiving Prostamax as part of anti-aging bioregulator protocols. It is frequently combined with Crystagen and Vesilut for comprehensive lower urinary tract support.
Quick Reference
| Literature-Reported Dose Range | 1–2 mg per injection |
| Literature-Reported Frequency | Once daily |
| Sites Reported in Studies | SubQ: abdomen, thigh, or upper arm |
| Literature-Reported Cycle Length | 20–30 days per course |
| Literature-Reported Washout | 2–3 courses per year; minimum 2 months off, 2–3× per year |
| Storage | Refrigerate reconstituted solution; oral capsules at room temperature |
| Timing | AM or PM, consistent daily timing |
Research Indications
Prostate Health
Chronic Prostatitis Management
Preclinical studies demonstrate reduced inflammation (swelling, hyperemia, lymphoid infiltration) and prevention of sclerotic/atrophic processes in chronic aseptic prostatitis models
Tissue Regeneration
Enhanced proliferative and metabolic activity in prostate epithelial cells and fibroblasts, maintaining efficacy in aged tissue samples
Superior to Conventional Agents
Preclinical efficacy surpassed Serenoa repens extract and animal prostate-derived medications in comparative studies
Anti-Aging
Chromatin Decondensation
Induces deheterochromatinization in human lymphocytes, potentially reactivating genes suppressed during aging through pericentromeric chromatin relaxation
Epigenetic Modulation
Affects ribosome gene activation and chromosomal structural patterns (chromosomes 1, 9, 16) in elderly subjects aged 75-88 years
Cellular Aging Research
Part of the Khavinson peptide family studied for geroprotective effects, with long-term Russian clinical protocols showing benefits in elderly populations
Immune
Lymphocyte Function Optimization
Studies show effects on lymphocyte chromatin organization, potentially improving immune cell function through gene expression modulation
Nucleolus Organizer Activation
Heightened Ag-positive nucleolus organizer regions observed, suggesting enhanced ribosomal gene activity
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Prostate Health Support | 0.5–2 mg daily | Once daily | SubQ |
| Anti-Aging Protocol | 0.5–2 mg daily | Once daily | SubQ or Oral |
| Oral Protocol | 0.5–2 mg | Once daily on empty stomach | Oral capsule |
Timing
Recommended administration window: morning administration, on empty stomach if oral. Typical onset: effects may take 2-4 weeks; protocol duration 10-20 days.
Peptide Interactions
Both are Khavinson bioregulators with complementary mechanisms. Prostamax targets prostate tissue while Epitalon focuses on telomerase activation. Russian protocols combine multiple bioregulators for comprehensive anti-aging support.
Safe combination supporting prostate-immune axis. Both are short Khavinson peptides with different tissue specificities. Long-term Russian studies show safety of multi-peptide bioregulator protocols.
Different target tissues with no known interactions. Pinealon targets neurological pathways while Prostamax focuses on prostate tissue. Can be used in comprehensive bioregulator protocols.
Different mechanisms with no documented interactions. BPC-157 focuses on tissue repair and GI protection while Prostamax provides prostate-specific bioregulation.
Both affect prostate tissue - effects may overlap or be amplified. Monitor for enhanced effects and consult healthcare provider if using together.
Both influence prostate tissue. Theoretical concern for combined effects on prostate growth. Monitor PSA levels and prostate symptoms if using together.
Preclinical studies compared Prostamax favorably to Serenoa repens extract. Different mechanisms - may provide complementary prostate support.
Reported Research Timeline
01Week 1–2 (reported in cited studies): subtle changes may begin; preclinical models show early anti-inflammatory effects
02Week 2–3 (reported in cited studies): enhanced cellular activity and tissue function based on animal research
03Week 3–4 (reported in cited studies): peak protocol effects in preclinical studies
Note: Human clinical data is limited - expectations based on preclinical research and similar Khavinson peptides
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Human clinical trial data not yet published - all dosing extrapolated from preclinical models
Possible side effects include mild injection site reactions, occasional digestive discomfort, and rare headache
Not Recommended when active prostate cancer exists - theoretical concern for stimulating tumor growth
Not recommended during pregnancy, lactation, or in women generally (prostate-specific)
Quality sourcing critical - poor manufacturing can result in contamination causing adverse reactions
Consult healthcare provider before use, especially if taking prostate medications or androgen therapy
Seek Medical Attention If:
Persistent injection site reactions or signs of infection
Unusual urinary symptoms or significant prostate discomfort
Signs of allergic reaction (rash, swelling, difficulty breathing)
Severe or persistent digestive issues
Significant fatigue or headache
Any concerning symptoms - discontinue and consult healthcare provider
Quality Indicators
Verified Marker
White Lyophilized Powder
Prostamax should appear as white to off-white freeze-dried powder indicating proper manufacture and storage
Verified Marker
Clear Reconstituted Solution
When properly mixed with bacteriostatic water, solution should be crystal clear with no particles
Verified Marker
Third-Party Testing
Reputable sources provide certificates of analysis showing 99%+ purity and absence of contaminants
Acceptable Range
Research Grade Only
Prostamax is sold as a research peptide and is not approved for human consumption in most countries
Quality Concern
Discolored Powder
Yellow, brown, or heavily clumped powder indicates degradation from heat or moisture exposure
Quality Concern
Cloudy or Particulate Solution
Persistent cloudiness, particles, or precipitates indicate contaminated or degraded peptide
Research Citations
- Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications
Borovskaya, T.G., Pakhomova, A.V., Goldberg, V.E., et al., 2013, Modern Research in Inflammation - Effects of short peptides on lymphocyte chromatin in senile subjects
Khavinson, V.K., Lezhava, T.A., Malinin, V.V., 2004, Bulletin of Experimental Biology and Medicine - The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ
Meskhi, T., Khachidze, D., Barbakadze, Sh., et al., 2004, Biofizika - Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)
Dzhokhadze, T.A., Buadze, T.Z., Gaĭozishvili, M.N., et al., 2012, Georgian Medical News - Peptide bioregulators: the new class of geroprotectors
Khavinson, V.K., 2022, Advances in Gerontology
Research Focus
Prostate health, BPH, Anti-aging, Prostate tissue restoration, Male urological health
Verified Vendors Carrying Prostamax
Frequently Asked Questions
What should researchers watch for with Prostamax?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Prostamax?
Week 1–2 (reported in cited studies): subtle changes may begin; preclinical models show early anti-inflammatory effects
How is Prostamax typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →